Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by All Cardiff Authors

Number of items: 5.

Mian, Afsar Ali, Haberbosch, Isabella, Khamaisie, Hazem, Agbarya, Abed, Pietsch, Larissa, Eshel, Elizabeh, Najib, Dally, Chiriches, Claudia, Ottmann, Oliver, Hantschel, Oliver, Biondi, Ricardo M., Ruthardt, Martin and Mahajna, Jamal 2021. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR/ABL1 and its resistance and compound mutants BCR/ABL1T315I and BCR/ABL1T315I-E255K. Annals of Hematology 100 , pp. 2023-2029. 10.1007/s00277-020-04357-z
file

Mian, Afsar A., Baumann, Ines, Liebermann, Marcus, Grebien, Florian, Superti-Furga, Giulio, Ruthardt, Martin, Ottmann, Oliver G. and Hantschel, Oliver 2019. The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis. Leukemia 33 , pp. 2319-2323. 10.1038/s41375-019-0468-y
file

Legut, Mateusz, Dolton, Garry, Mian, Afsar, Ottmann, Oliver and Sewell, Andrew 2018. CRISPR-mediated TCR replacement generates superior anticancer transgenic T-cells. Blood 131 (3) , pp. 311-322. 10.1182/blood-2017-05-787598
file

Haberbosch, Isabella, Rafiei, Anahita, Oancea, Claudia, Ottmann, Oliver, Ruthardt, Martin and Mian, Afsar 2016. BCR: a new target in resistance mediated by BCR/ABL-315I? Genes & Cancer 7 (1-2) , pp. 36-46.

Beissert, Tim, Hundertmark, Alena, Kaburova, Velina, Travaglini, Lorena, Mian, Afsar A., Nervi, Clara and Ruthardt, Martin 2008. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. International Journal of Cancer 122 (12) , pp. 2744-2752. 10.1002/ijc.23467

This list was generated on Tue Jun 28 07:10:20 2022 BST.